Abstract: A compound of the general formula (I) or pharmaceutically acceptable prodrugs, salts, hydrates, solvates, crystal forms or diastereomers thereof is described. A method of treating tyrosine kinase-associated disease states in a subject using a compound of formula (I) is also described.
Type:
Grant
Filed:
December 15, 2003
Date of Patent:
October 4, 2011
Assignee:
YM Biosciences Australia Pty Ltd
Inventors:
Christopher John Burns, Marcel Robert Kling
Abstract: Compounds of general formula (I), (II) (III) and (V) are described for use in modulating microtubule polymerisation and in the treatment of associated disease states. Use of compounds (I), (III) and (V) in the treatment of kinase-associated disease states is also described. Further described are novel compounds of formula (II), (III) and (V).
Type:
Grant
Filed:
December 3, 2004
Date of Patent:
July 19, 2011
Assignee:
YM Biosciences Australia Pty Ltd
Inventors:
Christopher John Burns, Andrew Frederick Wilks, Michael Francis Harte, Harrison Sikanyika, Emmanuelle Fantino
Abstract: The present invention relates to N-containing heterocyclic compounds that are inhibitors of protein kinases including JAK kinases. In particular, the compounds are selective for JAK1, JAK2, JAK3 or TYK2 kinases and combinations thereof such as JAK1 and JAK2. The kinase inhibitors can be used in the treatment of kinase associated diseases such as immunological and inflammatory diseases including organ transplants; hyperproliferative diseases including cancer and myeloproliferative diseases; viral diseases; metabolic diseases; and vascular diseases.
Type:
Application
Filed:
November 14, 2008
Publication date:
April 21, 2011
Applicant:
YM BIOSCIENCES AUSTRALIA PTY LTD
Inventors:
David Gerard Bourke, Christopher John Burns, Antony Nicholas Cuzzupe, John Thomas Feutrill, Marcel Robert Kling, Tracy Leah Nero
Abstract: The present invention provides a method of selecting or designing a compound for the ability to regulate JAK activity. The method comprises assessing the ability of the compound to modulate the interaction of the pseudo-substrate loop (PSL) with the kinase like domain (KLD) of JAK. In addition the present invention provides compounds which inhibit JAK and methods of treatment of JAK-associated disease states.
Type:
Grant
Filed:
October 5, 2006
Date of Patent:
September 14, 2010
Assignee:
YM Biosciences Australia Pty Ltd
Inventors:
Andrew Frederick Wilks, Julie Atkin, Emmanuelle Fantino
Abstract: A compound of general formula (I) or pharmaceutically acceptable prodrugs, salts, hydrates, solvates, crystal forms or diastereomers thereof is described. A method of treating kinase-associated disease states using the compound of formula (I) is also described.
Type:
Grant
Filed:
December 3, 2004
Date of Patent:
June 15, 2010
Assignee:
YM Biosciences Australia Pty Ltd
Inventors:
Christopher John Burns, Andrew Frederick Wilks, Xianyong Bu